MANNKIND CORP Cost of Goods Sold (Deprecated 2018-01-31)
MANNKIND CORP (MNKD) reported Cost of Goods Sold (Deprecated 2018-01-31) of $4.01 million for the 3-month period ending 2018-03-31, per its 10-Q filed 2018-05-09.
Discontinued › Expense Statement
us-gaap:CostOfGoodsSold · last filed 2018-05-09
- MANNKIND CORP cost of goods sold (deprecated 2018-01-31) for the quarter ending 2018-03-31 was $4.01M, a 57.30% increase year-over-year.
- MANNKIND CORP cost of goods sold (deprecated 2018-01-31) for the quarter ending 2017-12-31 was $5.02M, a 19.22% increase year-over-year.
- MANNKIND CORP cost of goods sold (deprecated 2018-01-31) for the quarter ending 2017-09-30 was $4.58M, a 4.12% increase year-over-year.
- MANNKIND CORP cost of goods sold (deprecated 2018-01-31) for the quarter ending 2017-06-30 was $5.09M, a 25.74% increase year-over-year.
- MANNKIND CORP cost of goods sold (deprecated 2018-01-31) for fiscal 2017 was $17.23M, a 0.62% increase from fiscal 2016.
- MANNKIND CORP cost of goods sold (deprecated 2018-01-31) for fiscal 2016 was $17.12M, a 73.56% decline from fiscal 2015.
- MANNKIND CORP cost of goods sold (deprecated 2018-01-31) for fiscal 2015 was $64.75M.
| Period end | Cost of Goods Sold (Deprecated 2018-01-31) 3 month | Cost of Goods Sold (Deprecated 2018-01-31) 3 month as first filed | Cost of Goods Sold (Deprecated 2018-01-31) 6 month | Cost of Goods Sold (Deprecated 2018-01-31) 9 month | Cost of Goods Sold (Deprecated 2018-01-31) 9 month as first filed | Cost of Goods Sold (Deprecated 2018-01-31) 12 month |
|---|---|---|---|---|---|---|
| 2018-03-31 | $4.01M 10-Q · filed 2018-05-09 | $9.03M derived: sum of 2 quarters · filed 2018-05-09 | $13.60M derived: sum of 3 quarters · filed 2018-05-09 | $18.69M derived: sum of 4 quarters · filed 2018-05-09 | ||
| 2017-12-31 | $5.02M derived: 10-K 12 month − 10-Q 9 month · filed 2018-02-27 | $9.59M derived: sum of 2 quarters · filed 2018-02-27 | $14.68M derived: sum of 3 quarters · filed 2018-02-27 | $17.23M 10-K · filed 2018-02-27 | ||
| 2017-09-30 | $4.58M 10-Q · filed 2017-11-07 | $9.66M derived: sum of 2 quarters · filed 2017-11-07 | $12.21M 10-Q · filed 2017-11-07 | $16.42M derived: sum of 4 quarters · filed 2018-05-09 | ||
| 2017-06-30 | $5.09M 10-Q · filed 2017-08-07 | $7.63M 10-Q · filed 2017-08-07 | $11.84M derived: sum of 3 quarters · filed 2018-05-09 | $16.24M derived: sum of 4 quarters · filed 2018-05-09 | ||
| 2017-03-31 | $2.55M 10-Q · filed 2018-05-09 | $6.76M derived: sum of 2 quarters · filed 2018-05-09 | $11.15M derived: sum of 3 quarters · filed 2018-05-09 | $15.20M derived: sum of 4 quarters · filed 2018-05-09 | ||
| 2016-12-31 | $4.21M derived: 10-K 12 month − 10-Q 9 month · filed 2018-02-27 | $8.60M derived: sum of 2 quarters · filed 2018-02-27 | $12.65M derived: sum of 3 quarters · filed 2018-02-27 | $17.12M 10-K · filed 2018-02-27 | ||
| 2016-09-30 | $4.39M 10-Q · filed 2017-11-07 | $4.33M 10-Q · filed 2016-11-09 | $8.44M derived: sum of 2 quarters · filed 2017-11-07 | $12.91M 10-Q · filed 2017-11-07 | $15.57M 10-Q · filed 2016-11-09 | $62.66M derived: sum of 4 quarters · filed 2018-02-27 |
| 2016-06-30 | $4.04M 10-Q · filed 2017-08-07 | $9.21M 10-Q · filed 2017-08-07 | $58.27M derived: sum of 3 quarters · filed 2018-02-27 | $66.39M derived: sum of 4 quarters · filed 2018-02-27 | ||
| 2016-03-31 | $5.17M 10-Q · filed 2017-05-10 | $54.23M derived: sum of 2 quarters · filed 2018-02-27 | $62.34M derived: sum of 3 quarters · filed 2018-02-27 | |||
| 2015-12-31 | $49.06M derived: 10-K 12 month − 10-Q 9 month · filed 2018-02-27 | $57.17M derived: sum of 2 quarters · filed 2018-02-27 | $64.75M 10-K · filed 2018-02-27 | |||
| 2015-09-30 | $8.12M 10-Q · filed 2016-11-09 | $15.69M 10-Q · filed 2016-11-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Alto Neuroscience, Inc. (ANRO) | United States | $1.065B | -11.02 |
| Savara Inc (SVRA) | United States | $1.044B | -9.10 |
| MoonLake Immunotherapeutics (MLTX) | Switzerland | $1.031B | -5.43 |
| Pacira BioSciences, Inc. (PCRX) | United States | $1.020B | 69.03 |
| Janux Therapeutics, Inc. (JANX) | United States | $1.019B | -9.15 |
| Amphastar Pharmaceuticals, Inc. (AMPH) | United States | $1.116B | 10.93 |
| Corvus Pharmaceuticals, Inc. (CRVS) | United States | $0.994B | -23.25 |
| Seaport Therapeutics, Inc. (SPTX) | United States | $1.131B | |
| Kura Oncology, Inc. (KURA) | United States | $0.967B | -3.29 |
| Arbutus Biopharma Corp (ABUS) | $0.965B | 6.19 |